Subscribe

Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine Search
UPC draws hard line on urgency in first SPC dispute
Europe
UPC draws hard line on urgency in first SPC dispute
The Paris Local Division says Merz ran out of time to stop Viatris' multiple sclerosis generic, clarifying the court’s urgency standards in the process.   1 December 2025
Patent and SPC litigator makes the move from Carpmaels
Europe
Patent and SPC litigator makes the move from Carpmaels
Joining an expanding IP litigation practice, the new partner adds experience in patent, SPC and multi-jurisdictional disputes across pharma, technology, and medical devices.   1 December 2025
EU Pharma Package hits the final stretch—but can negotiators agree?
Europe
EU Pharma Package hits the final stretch—but can negotiators agree?
With EU trilogues deadlocked over the package, the future of drug exclusivities and access-linked obligations hangs in the balance. Jackie Mulryne and Paul Ranson of Morgan Lewis pinpoint the flashpoints to watch as negotiators push for a year-end deal.   28 November 2025
Europe
UPC appeals court hands Amgen a win in cholesterol dispute
The Court of Appeal has overturned a ruling that revoked the pharma company’s cholesterol-lowering antibody patent, clarifying key principles for assessing inventive step.   27 November 2025
Americas
Squires affirms USPTO’s stance on AI with revised guidance
Director Squires rescinds previous guidelines and clarifies that there is no separate, modified inventorship standard for AI-assisted inventions.   27 November 2025
Europe
UPC judges call for greater female advocacy at court
Even when legal teams do include women, the judges say they don’t always see or hear them, emphasising that visibility is critical for aspiring advocates.   27 November 2025
Big Pharma
The clinical trial dilemma: Navigating European practice
Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.   27 November 2025
Americas
Novartis counsel on managing patents at a $50bn company
Balancing tight budgets while keeping up with fast-changing biosimilar rules is all in a day’s work for Novartis’s R&D IP team, but how do they stay on top of it all?   26 November 2025
Europe
Biotech cleared to make biosimilar of $6bn treatment after landmark ruling
Regeneron and Bayer suffered a UK setback as the court followed others in Europe in its interpretation of the so-called SPC manufacturing waiver.   25 November 2025
Careers
Ex-Teva counsel and FDA regulatory specialist returns to private practice
A regulatory counsel with nine years at the FDA and over two decades of patent experience has joined a firm in Washington, DC.   24 November 2025